Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29821277 | 1.00 | HSD17B10 (0.49) | HSD17B10HPGDKDM4EALDH1A1GLA | |
| SCHEMBL1538495 | 0.76 | SMN1; SMN2 (0.42) | HSD17B10HPGDKDM4ESMN1; SMN2TOP2A | |
| SCHEMBL796768 | 0.76 | NPM1 (0.43) | HSD17B10HPGDALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL29965863 | 0.76 | KDM4E (0.55) | HSD17B10HPGDKDM4EALDH1A1GLA | |
| SCHEMBL1417158 | 0.76 | KDM4E (0.55) | HSD17B10HPGDKDM4EALDH1A1GLA | |
| SCHEMBL30388793 | 0.75 | HRH4 (0.44) | HSD17B10KDM4EALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL15471902 | 0.75 | HRH4 (0.45) | HSD17B10KDM4EALDH1A1TOP2AMAPK1 | |
| SCHEMBL3328288 | 0.72 | LCK (0.45) | MAPK1 | |
| SCHEMBL5362222 | 0.72 | HCAR3 (0.49) | HSD17B10HPGDALDH1A1GAATSHR | |
| SCHEMBL21642536 | 0.71 | SMN1; SMN2 (0.45) | KDM4EALDH1A1GAASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981677-B2 | Further substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2024-05-14 | — | — | US | claimed |
| EP-3823970-B1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2024-01-03 | — | — | EP | claimed |
| EP-3567041-B1 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2023-12-27 | — | — | EP | claimed |
| CN-112771046-B | Other substituted triazoloquinoxaline derivatives | 格吕伦塔尔有限公司 | 2023-09-19 | — | — | CN | claimed |
| EP-3823971-B1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2022-07-27 | — | — | EP | claimed |
| EP-3823971-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-05-26 | — | — | EP | claimed |
| WO-2020016453-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2020-01-23 | — | — | WO | claimed |
| EP-1456210-B1 | PYRAZOLYL-SUBSTITUTED TRIAZOLOQUINOXALINES | JSW RES FORSCHUNGSLABOR GMBH (AT) | 2006-02-22 | — | — | EP | claimed |
| US-20050107611-A1 | Pyrazolyl-substituted triazoloquinoxalines | JSW-RESEARCH FORSCHUNGSLABOR GMBH (AT) | 2005-05-19 | — | — | US | claimed |
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-08-05 | — | — | US | claimed |
| EP-1177797-A9 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | claimed |
| EP-1177797-A1 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-06 | — | — | EP | claimed |
| EP-0745154-B1 | MULTICOMPONENT SYSTEM FOR MODIFYING, DECOMPOSING OR BLEACHING LIGNIN, LIGNIN-CONTAINING MATERIALS OR SIMILAR SUBSTANCES AND METHOD OF USING THIS SYSTEM | LIGNOZYM GMBH (DE) | 1998-09-16 | — | — | EP | claimed |
| EP-0845026-A1 | MULTICOMPONENT SYSTEM FOR USE WITH DETERGENT SUBSTANCES | CALL, Hans-Peter Dr. (DE) | 1998-06-03 | — | — | EP | claimed |
| WO-1997048786-A1 | MULTICOMPONENT SYSTEM FOR USE WITH DETERGENT SUBSTANCES | CALL HANS PETER (DE) | 1997-12-24 | — | — | WO | claimed |
| US-4008322-A | RICE BLAST | ELI LILLY AND COMPANY (US) | 1977-02-15 | — | — | US | claimed |
| JP-6128262-A | — | — | None | — | — | JP | disclosed |
| EP-4090660-B1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2024-01-31 | — | — | EP | disclosed |
| US-4252954-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-02-24 | — | — | US | disclosed |
| US-4008322-A | RICE BLAST | ELI LILLY AND COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | ADORA2A, ADORA1, ADORA2B | HSD17B10 3368/4885HPGD 1304/4885KDM4E 4617/4885 |
| US-11981677-B2 | Further substituted triazolo quinoxaline derivatives | NR3C1, GRK5, NR3C2 | HSD17B10 778/4885HPGD 199/4885KDM4E 4106/4885 |
| US-20050107611-A1 | Pyrazolyl-substituted triazoloquinoxalines | P2RY1, P2RX5, P2RX1 | HSD17B10 4453/4885HPGD 819/4885KDM4E 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.